Harmonex Neuroscience Research
Dothan, Alabama, United States
Research institute in Dothan, Alabama
408 Healthwest Dr, Dothan, AL 36303
About Harmonex Neuroscience Research
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Shire
11
Sunovion
8
Forest Laboratories
4
Naurex, Inc, an affiliate of Allergan plc
4
Hoffmann-La Roche
3
Emalex Biosciences Inc.
2
Janssen Research & Development, LLC
2
Otsuka Pharmaceutical Development & Commercialization, Inc.
2
Pfizer
2
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2
Supernus Pharmaceuticals, Inc.
2
Clinical Trials at Harmonex Neuroscience Research
During the past decade, Harmonex Neuroscience Research conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 31 clinical trials were completed, i.e. on
average, 103.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 16 clinical trials were completed. i.e. 533.3%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
2006-06-01
2008-06-01
Completed
218
Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
2006-09-01
2009-06-01
Completed
330
Efficacy and Safety of SPD503 in Combination With Psychostimulants
2008-09-02
2009-12-10
Completed
461
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
2011-09-19
2013-05-16
Completed
314
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
2010-05-11
2013-06-03
Completed
528
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate
2010-06-28
2012-07-19
Completed
267
Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
2011-03-01
2012-06-01
Completed
215
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Harmonex Neuroscience Research" #1 sponsor was "Shire" with 11 trials, followed by "Sunovion" with 8 trials
sponsored, "Forest Laboratories" with 4 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored and "Hoffmann-La Roche"
with 4 trials sponsored. Other sponsors include 15 different institutions and
companies that sponsored additional 19 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Harmonex Neuroscience Research"
#1 collaborator was "Otsuka America Pharmaceutical" with 2 trials as a collaborator, "Takeda Development Center Americas, Inc." with 1 trials as a collaborator and "The Emmes Company, LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Harmonex Neuroscience Research
According to Clinical.Site data, the most researched conditions in "Harmonex Neuroscience Research" are
"Attention Deficit Hyperactivity Disorder (ADHD)" (6 trials), "Autism Spectrum Disorder" (5 trials), "Depressive Disorder, Major" (5 trials), "Major Depressive Disorder" (5 trials) and "ADHD" (3 trials). Many other conditions were trialed in "Harmonex Neuroscience Research" in a lesser frequency.
Clinical Trials Intervention Types at Harmonex Neuroscience Research
Most popular intervention types in "Harmonex Neuroscience Research" are "Drug" (47 trials), "Other" (4 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (25 trials), "Aripiprazole" (4 trials), "Lurasidone" (4 trials), "Rapastinel" (4 trials) and "SHP465" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Harmonex Neuroscience Research
The vast majority of trials in "Harmonex Neuroscience Research" are
50 trials for "All" genders.
Clinical Trials Status at Harmonex Neuroscience Research
Currently, there are NaN active trials in "Harmonex Neuroscience Research".
undefined are not yet recruiting,
4 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 38 completed trials in Harmonex Neuroscience Research,
undefined suspended trials,
and 7 terminated clinical trials to date.
Out of the total trials that were conducted in Harmonex Neuroscience Research, 1 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 37 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 4 trials, and there were
also 1 trials that are defined as “Not Applicable".